Therapy resistance conferred by MRP1 SNPs might be an effect dominant in relapsed or progressive disease, when sensitive AML subclones are eliminated by cytotoxic chemotherapy and resistant blasts expressing MRP1 SNPs proliferate in contrast to their chemosensitive counterparts. The gene discussed is ABCC1; the disease is acute myeloid leukemia.